Akebia $AKBA has struck a landmark $1 billion partnership with Otsuka for its late-stage drug vadadustat, an oral treatment for anemia related to chronic kidney disease. The deal comes with $265 million in committed cash, including $125 million as an upfront payment with another $35 million due in early 2017.
Otsuka gains co-commercialization rights in the US for Akebia’s drug, handing over $105 million to help cover development costs and offering milestones reaching up to $765 million.
That all marks a big score for Akebia, which saw its shares spike 43% on the news this morning.
“This collaboration achieves our goal of funding our global PRO2TECT and INNO2VATE Phase 3 studies for vadadustat while retaining significant long-term value for Akebia,” said Akebia CEO John P. Butler.
Like rival FibroGen $FGEN, Akebia is working on stimulating the production of red blood cells by mimicking the effect of high altitude on humans. And it hopes to tackle ESAs from Amgen, a market worth billions in annual income.
Mitsubishi Tanabe struck a $350 million deal with Cambridge, MA-based Akebia for the Asian rights to this drug back in late 2015.
The best place to read Endpoints News? In your inbox.
Comprehensive daily news report for those who discover, develop, and market drugs. Join 45,000+ biopharma pros who read Endpoints News by email every day.Free Subscription